Approved Drug May Be Repurposed to Treat Tumors Resulting From NF2-Related Schwannomatosis
June 22, 2024
June 22, 2024
BOSTON, Massachusetts, June 22 (TNSres) -- Massachusetts General Hospital issued the following news release:
* * *
Key Takeaways
* Researchers have found promising evidence that brigatinib, a small molecule treatment approved for the treatment of lung cancer, helps to shrink the tumors of patients with NF2-related schwannomatosis
* Using a highly innovative phase 2 platform-basket trial design, the multi-center team found that brigatinib shrunk . . .
* * *
Key Takeaways
* Researchers have found promising evidence that brigatinib, a small molecule treatment approved for the treatment of lung cancer, helps to shrink the tumors of patients with NF2-related schwannomatosis
* Using a highly innovative phase 2 platform-basket trial design, the multi-center team found that brigatinib shrunk . . .